LCM
MRKR icon

Laurion Capital Management’s Marker Therapeutics MRKR Stock Holding History

Laurion Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-21,170
Closed -$1.4M – 1084
2019
Q1 		$1.4M Buy
21,170
+9,738
+85% +$569K 0.02% 459
2018
Q4 		$634K Buy
+11,432
New +$833K 0.01% 654

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Laurion Capital Management's MRKR Position: Q2 2019 in Review

Laurion Capital Management sold out of Marker Therapeutics (MRKR) in Q2 2019, closing a stake of 21,170 shares — an estimated $1.4M sold.

Laurion Capital Management first reported a position in MRKR in Q4 2018 and held it in 2 quarters. The position peaked at $1.4M in Q1 2019. 70 funds tracked by Wall St. Rank hold MRKR as of Q2 2019.

  • Laurion Capital Management reported no remaining Marker Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Laurion Capital Management sold 21,170 Marker Therapeutics shares in Q2 2019, an estimated $1.4M.
  • Laurion Capital Management first reported a position in Marker Therapeutics in Q4 2018 and held it in 2 quarters.
  • Laurion Capital Management's Marker Therapeutics position peaked at $1.4M in Q1 2019.
  • 70 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2019.

Based on Laurion Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.